FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Related Keywords

Heidelberg ,Baden Wüberg ,Germany ,Ashling Wahner ,Bernd Kasper ,University Of Heidelberg ,Facebook ,Linkedin ,Twitter ,Live On Air ,Springworks Therapeutics ,Sarcoma Unit ,Interdisciplinary Tumor Center Mannheim ,Mannheim University Medical Center ,Onclive On Air ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,Phd ,Fda Approval Of Nirogacestat ,Patients With Desmoid Tumors ,The University Of Heidelberg ,